drugset / Trial / NCT01051544

Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive

NCT01051544 ↗

RandomizedParallel-groupOpen-labelPrevention

Summary

This is a prospective, controlled, randomized, open label study, aimed at comparing FVIII/VWF concentrates with FVIII concentrates at 200 IU/kg daily in their ability to induce immune tolerance in Haemophilia A patients with high responding inhibitors and poor prognosis for success.

Timeline

Start
2009-09-25
Primary completion
2020-06-25
Completion
2020-06-25

Outcome

Outcome not reported

Stopped: “complete per PI”

Drugs

EvaluationDrugModalityDoseRoute
Comparator ADVATE Protein / enzyme biologic 200 iu/kg —
Comparator Beriate P Protein / enzyme biologic 200 iu/kg —
Comparator Emoclot DI Protein / enzyme biologic 200 iu/kg Other
Comparator FVIII/VWF concentrates Protein / enzyme biologic 200 iu/kg Other
Comparator Factane Protein / enzyme biologic 200 iu/kg Other
Comparator Fahndi Protein / enzyme biologic 200 iu/kg Other
Comparator Haemoctine SDH Protein / enzyme biologic 200 iu/kg Other
Comparator Helixate Protein / enzyme biologic 200 iu/kg —
Comparator Hemofil M Protein / enzyme biologic 200 iu/kg —
Comparator Koate-DVI Protein / enzyme biologic 200 iu/kg Other
Comparator Kogenate SF Protein / enzyme biologic 200 iu/kg —
Comparator Monarch M Protein / enzyme biologic 200 iu/kg —
Comparator Monoclate Protein / enzyme biologic 200 iu/kg —
Comparator Moroctocog alfa Protein / enzyme biologic 200 iu/kg —
Comparator Optivate Protein / enzyme biologic 200 iu/kg Other
Comparator Replenate Protein / enzyme biologic 200 iu/kg —
Comparator Wilate Protein / enzyme biologic 200 iu/kg Other

Indications